{"analyses":[{"ciLowerLimit":"-2.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.3","groupDescription":"Without PET","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.33","paramType":"Absolute difference in %","paramValue":"1.6","statisticalMethod":"Log Rank"},{"ciLowerLimit":"-2.3","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.4","groupDescription":"With PET","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.17","paramType":"Absolute difference in %","paramValue":"3.5","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7"},{"groupId":"OG001","value":"87.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"599"},{"groupId":"OG001","value":"613"}],"units":"Participants"}],"title":"Without PET"},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8"},{"groupId":"OG001","value":"85.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"270"},{"groupId":"OG001","value":"274"}],"units":"Participants"}],"title":"With PET"}],"denoms":[{"counts":[{"groupId":"OG000","value":"699"},{"groupId":"OG001","value":"702"}],"units":"Participants"}],"description":"Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as \\>=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by \\>/= 50%; Overall Response (OR) = CR + PR.","groups":[{"description":"Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG000","title":"Rituximab+Chemotherapy"},{"description":"Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.","id":"OG001","title":"Obinutuzumab+Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ITT population defined as all randomized participants grouped according to their randomized treatment arm regardless of what treatments were actually received.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of induction period (up to approximately 7 months)","title":"Overall Response (Overall Study Population), Investigator-Assessed","type":"SECONDARY","unitOfMeasure":"percentage of participants with event"}